Pharmaceuticals Search Engine [selected websites]

Wednesday, October 27, 2010

LFB Biomédicaments : New Liquid Intravenous Immunoglobulin CLAIRYG® Available in France as of August 30

LFB Biomédicaments09/09/2010 - CLAIRYG®, a new 5% concentrated, ready-to-use liquid intravenous immunoglobulin, is being launched in France in September 2010. CLAIRYG® is indicated for the treatment of primitive and secondary immunodeficiency and certain autoimmune and systemic deficiencies.
About CLAIRYG®
CLAIRYG® is an intravenous immunoglobulin produced through a purification process involving state-of-the-art technological innovations to ensure high levels of immunoglobulin G (IgG) purity and biological safety.
LFB Biomédicaments obtained marketing authorisation from AFSSAPS for CLAIRYG® in December 2009.
Manufacturing stages particularly include caprylic acid fractionation, combined with ion exchange chromatography, accounting for CLAIRYG®’s great IgG purity and its very low anti-A and anti-B hemagglutinin content. The functional wholeness and physiological distribution of IgG sub-classes of CLAIRYG® are maintained in a unique, proprietary excipient formulation...

[...]

...About LFB:
LFB is a biopharmaceutical group that develops, manufactures and markets medicinal products for the treatment of serious and often rare diseases in several major therapeutic fields, namely Immunology, Intensive Care and Hemostasis. The LFB Group is the leading manufacturer of plasma-derived medicinal products in France and 6th worldwide and is also among the leading European companies for the development of monoclonal antibodies and new-generation proteins based on biotechnologies. With its strong focus on research, the LFB Group is pursuing a growth strategy that seeks to extend its activities internationally and develop innovative therapies. In 2009, LFB invested €76 million in research & development, i.e. 20% of its €376 million turnover. LFB Group is chaired by Christian Béchon and employs 1,700 people... LFB's Press Release - communiqué de presse LFB -

Thursday, October 21, 2010

Venn Life Sciences : Acquisition of DCI France

October 19th 2010 – Venn Life Sciences a multinational Clinical Research Organisation (CRO) announced that it has acquired French CRO, DCI.

DCI développement clinique international
DCI, a Paris based CRO, was founded by Dr. Frédérique Cabrières in 1989 and offers two types of specialised services to clients: clinical trial management services for Phase I-IV and contract placement solutions for clinical research projects. DCI bring quality and value to client’s clinical trial programs by offering flexibility of services coupled with extensive knowledge of the French clinical trial industry. With over 20 years experience DCI counts some of the world’s leading pharmaceutical and biotech companies among its clients... Venn Life Sciences' Press Release -

Wednesday, October 13, 2010

Nutriset : Malnutrition, The Plumpy’nut® patent now accessible on-line

NutrisetRouen/Marseille, October 13, 2010 – Just before World Food Day, the French Institute of Research for Development (IRD) and Nutriset intensify their action against malnutrition in developing countries.

They announce a simple and innovative system, online, to access their patents to promote the production of ready-to-use foods of the Plumpy’nut® type.

Henceforth, in developing countries where Nutriset and the IRD have registered a patent, local companies will be able to obtain a “Patent Usage Agreement” in just a few clicks. This agreement will enable them to use the patent to develop and market their own products with humanitarian aid organizations.

This simplified mechanism is consistent with the mutual objective of Nutriset and the IRD of strengthening the nutritional autonomy of countries and populations affected by malnutrition.

The original Ready-to-Use Therapeutic Food (RUTF), Plumpy’nut, developed in 1996, is the result of joint research conducted by Michel Lescanne, founder of Nutriset, and André Briend, a doctor and nutritionist conducting research at the IRD. “Our aim was to make the management of severe acute malnutrition easier, more efficient and accessible to a greater number of children” recalls Michel Lescanne. “We also wanted it to be possible to produce our product in developing countries with initial local production experiments conducted as early as 1997.”

Derived from this innovation, Nutriset developed a range of products for the prevention or treatment of different forms of malnutrition: Supplementary’Plumpy®, Plumpy’doz®, Plumpy’soy®, Nutributter®, QBmix®, etc. The Plumpy® range products are currently massively used by humanitarian organisations and health ministries that aid populations affected by malnutrition. Since their development, it is estimated nearly 7 million children benefitted from the Plumpy® range products... Nutriset's Press Release - communiqué de presse Nutriset -

Nutriset, an overview

25 years of experience, research and innovation for the benefit of children; an operation 100% dedicated to humanitarian and welfare initiatives in developing countries.
An ambitious mandate for the company set by its founder, Michel Lescanne:
To invent, produce and make accessible solutions for the treatment and prevention of malnutrition and so contribute to the nutritional autonomy of developing countries.
A major innovation in 1996: Plumpy’nut®, the first ready-to-use therapeutic food (RUTF), made possible a revolution in the management of malnutrition, increasing the number of children treated and improving the recovery rate.... Nutriset, an overview - Nutriset, en bref -

Wednesday, October 6, 2010

ICDD : Launching of Mitosafe® at ToxEXPO

icdd sas innovative concepts in drug developmentMarch 2010 - Launching of Mitosafe® at ToxEXPO.

• The Mitosafe® platform is focused on a mechanistic analysis of mitochondrial functions
• The Mitostream® platform is a high content and phenotypic analysis of mitochondrial behavior. It aims at a better anticipation of the clinical tolerance of drugs early in the drug development process....ICDD's news release -

About ICDD
Founded in 2007, ICDD-sas is a science-based company, established as a contract research provider and with its activities focused on predictive toxicology. ICDD-sas uses its proprietary secondary screening platforms to select the safest drugs from the most active lead molecules developed and provided by our clients.

ICDD-sas is located close to Aix-en-Provence, France, in a state of the art Euro 2 million facility, covering 1600 square metres that acts as an incubator for emerging companies developing and commercializing innovative technologies.
The scientists at ICDD-sas boast a combined experience of 40 years in drug development, biochemistry, cell biology, neuroscience and immunology, having analyzed more than 100 new chemical entities at different stages of pre-clinical & clinical development.

The Drug Development Need
Drug development costs have increased 4-fold in the last 20 years, while the new treatments reaching the market each year have declined by almost 50%. Drug failure is usually due either to unexpected human toxicity or otherwise because of a lack of efficacy. Toxicity and lack of efficacy are often discovered only late in the costly clinical development program. ICDD-sas, using its proprietary know how, effectively addresses both of these challenges thereby enhancing the development of safer, more effective medicines, whilst reducing late stage development failures, development time and costs... About ICDD -